Literature DB >> 35700331

Ph-like gene alterations and complex chromosomal abnormalities are frequent in patients with acute lymphoblastic leukemia experiencing relapse after allogeneic hematopoietic cell transplantation.

Sean I Tracy1, Qing Cao1, Ben Bachan2, Matthew Meredith1, LeAnn Oseth1, Daniel Weisdorf1, Claudio Brunstein1, Betsy Hirsch1, Veronika Bachanova1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35700331      PMCID： PMC9474703          DOI： 10.1111/ejh.13814

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   3.674


× No keyword cloud information.
  13 in total

1.  The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia.

Authors:  Moshe Yeshurun; Daniel Weisdorf; Jacob M Rowe; Martin S Tallman; Mei-Jie Zhang; Hai-Lin Wang; Wael Saber; Marcos de Lima; Brenda M Sandmaier; Geoffrey Uy; Rammurti T Kamble; Mitchell S Cairo; Brenda W Cooper; Jean-Yves Cahn; Siddhartha Ganguly; Bruce Camitta; Leo F Verdonck; Christopher Dandoy; Miguel Angel Diaz; Bipin N Savani; Biju George; Jane Liesveld; Joseph McGuirk; Michael Byrne; Michael R Grunwald; William R Drobyski; Michael A Pulsipher; Hisham Abdel-Azim; Tim Prestidge; Matthew J Wieduwilt; Rodrigo Martino; Maxim Norkin; Amer Beitinjaneh; Sachiko Seo; Taiga Nishihori; Baldeep Wirk; Haydar Frangoul; Asad Bashey; Shahram Mori; David I Marks; Veronika Bachanova
Journal:  Blood Adv       Date:  2019-02-26

2.  Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.

Authors:  Nicola Gökbuget; Michael Kneba; Thorsten Raff; Heiko Trautmann; Claus-Rainer Bartram; Renate Arnold; Rainer Fietkau; Mathias Freund; Arnold Ganser; Wolf-Dieter Ludwig; Georg Maschmeyer; Harald Rieder; Stefan Schwartz; Hubert Serve; Eckhard Thiel; Monika Brüggemann; Dieter Hoelzer
Journal:  Blood       Date:  2012-03-22       Impact factor: 22.113

3.  Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.

Authors:  Nathalie Dhédin; Anne Huynh; Sébastien Maury; Reza Tabrizi; Kheira Beldjord; Vahid Asnafi; Xavier Thomas; Patrice Chevallier; Stéphanie Nguyen; Valérie Coiteux; Jean-Henri Bourhis; Yosr Hichri; Martine Escoffre-Barbe; Oumedaly Reman; Carlos Graux; Yves Chalandon; Didier Blaise; Urs Schanz; Véronique Lhéritier; Jean-Yves Cahn; Hervé Dombret; Norbert Ifrah
Journal:  Blood       Date:  2015-01-13       Impact factor: 22.113

4.  Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.

Authors:  Shanhao Tang; Hongjie Shen; Changju Qu; Haiping Dai; Xiaming Zhu; Shengli Xue; Zixuan Ding; Jing Lu; Depei Wu; Xiaowen Tang
Journal:  Bone Marrow Transplant       Date:  2018-06-25       Impact factor: 5.483

5.  Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia.

Authors:  Theodora Anagnostou; Ryan A Knudson; Kathryn E Pearce; Reid G Meyer; Beth A Pitel; Jess F Peterson; Linda B Baughn; Kaaren K Reichard; Rhett P Ketterling; Sara M Kloft-Nelson; Darlene L Knutson; Shakila P Khan; Naseema Gangat; Mark R Litzow; William J Hogan; Alexandra Wolanskyj; Aref Al-Kali; Kebede H Begna; Michelle Elliott; Animesh Pardanani; James Foran; Mithun Shah; Ayalew Tefferi; Hassan Alkhateeb; Kevin Halling; Vilmarie Rodriguez; Patricia T Greipp; Mrinal M Patnaik
Journal:  Am J Hematol       Date:  2020-01-26       Impact factor: 10.047

6.  The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.

Authors:  David I Marks; Tao Wang; Waleska S Pérez; Joseph H Antin; Edward Copelan; Robert Peter Gale; Biju George; Vikas Gupta; Joerg Halter; H Jean Khoury; Thomas R Klumpp; Hillard M Lazarus; Victor A Lewis; Philip McCarthy; David A Rizzieri; Mitchell Sabloff; Jeff Szer; Martin S Tallman; Daniel J Weisdorf
Journal:  Blood       Date:  2010-04-19       Impact factor: 22.113

7.  In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).

Authors:  Anthony H Goldstone; Susan M Richards; Hillard M Lazarus; Martin S Tallman; Georgina Buck; Adele K Fielding; Alan K Burnett; Raj Chopra; Peter H Wiernik; Letizia Foroni; Elisabeth Paietta; Mark R Litzow; David I Marks; Jill Durrant; Andrew McMillan; Ian M Franklin; Selina Luger; Niculae Ciobanu; Jacob M Rowe
Journal:  Blood       Date:  2007-11-29       Impact factor: 22.113

8.  Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study.

Authors:  Elias Jabbour; Keyur Patel; Nitin Jain; Dzifa Duose; Rajyalakshmi Luthra; Nicholas J Short; Gerhard Zugmaier; Anthony San Lucas; Kelly Velasco; Qui Tran; Faraz Zaman; Marina Konopleva; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2021-06-23       Impact factor: 10.047

9.  IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy.

Authors:  James C Chen; Rolando Perez-Lorenzo; Yvonne M Saenger; Charles G Drake; Angela M Christiano
Journal:  Cell Syst       Date:  2018-06-27       Impact factor: 10.304

10.  Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia.

Authors:  C Greil; M Engelhardt; G Ihorst; J Duque-Afonso; K Shoumariyeh; H Bertz; R Marks; R Zeiser; J Duyster; J Finke; R Wäsch
Journal:  Bone Marrow Transplant       Date:  2020-10-31       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.